Tumor-educated platelets in lung cancer

Area of Science:

• Oncology
• Molecular Diagnostics
• Biomarker Discovery

Background:

• Lung cancer (LC) remains a leading cause of cancer mortality globally.
• Non-invasive diagnostic and monitoring techniques are crucial for effective LC treatment.
• Tumor-educated platelets (TEPs) are emerging biomarkers with potential for comprehensive tumor insights.

Purpose of the Study:

• To review the role of TEPs in understanding tumor biology, metastasis, and treatment response in lung cancer.
• To highlight the diagnostic and prognostic capabilities of analyzing RNA within TEPs.
• To discuss the integration of advanced technologies for improving TEP-based diagnostics.

Main Methods:

• Review of current literature on platelet-tumor interactions and TEP biomarker applications.
• Analysis of RNA sequencing data from TEPs for LC detection and molecular profiling (EGFR, KRAS, ALK).
• Exploration of TEPs' utility in predicting responses to immunotherapy and targeted therapy.

Main Results:

• TEPs exhibit active RNA profiles influenced by tumor microenvironments, providing insights into cancer biology.
• Platelet RNA analysis demonstrates high accuracy in detecting LC and identifying specific oncogenic alterations.
• TEP-based RNA profiling shows promise for predicting treatment efficacy, particularly in immunotherapy and targeted therapy.

Conclusions:

• TEPs represent a groundbreaking, non-invasive approach for lung cancer diagnostics and therapeutic monitoring.
• Further standardization of TEP extraction and purification methods is necessary for clinical translation.
• Combining TEPs with other biomarkers like ctDNA and exosomal RNA can enhance early-stage LC diagnosis and personalized treatment strategies.